Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris

被引:23
作者
Soejima, H
Ogawa, H
Yasue, H
Nishiyama, K
Kaikita, K
Misumi, K
Takazoe, K
Kugiyama, K
Tsuji, I
Kumeda, K
Nakamura, S
机构
[1] Kumamoto Univ, Sch Med, Div Cardiol, Kumamoto 860, Japan
[2] ChemoSero Therapeut Res Inst, Kumamoto, Japan
[3] Kyoto Univ, Primate Res Inst, Dept Mol & Cellular Biol, Aichi, Japan
关键词
tissue factor; tissue factor pathway inhibitor;
D O I
10.1016/S0049-3848(98)00147-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The hypercoagulability is associated with expression of tissue factor in patients with angina. Tissue factor pathway inhibitor regulates the extrinsic coagulation pathway mediated by tissue factor. Plasma samples were obtained from 14 patients with angina pectoris and 9 with chest pain syndrome before and 5, 30, 60, and 120 minutes after administration of heparin (50 IU/kg). The tissue factor and prothrombin fragment 1+2 levels before administration were elevated in patients with angina pectoris and were reduced to the levels of chest pain syndrome after the administration. The free tissue factor pathway inhibitor levels after the administration were higher in patients with angina pectoris than in patients with chest pain syndrome. Plasma tissue factor pathway inhibitor levels correlated positively with plasma tissue factor and prothrombin fragment 1+2 levels. We showed that plasma-free TFPI levels after administration of heparin, which may indicate endothelial cell associated TFPI levels, increased in patients with angina pectoris compared with patients with chest pain syndrome. Increased endothelial cell associated TFPI was associated with hypercoagulability in patients with angina pectoris. These may help to explain the reduction in thrombotic risk associated with the use of heparin. (C) 1998 Elsevier Science Ltd.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 37 条
[1]   MAINTENANCE OF CORONARY PATENCY AFTER FIBRINOLYSIS WITH TISSUE FACTOR PATHWAY INHIBITOR [J].
ABENDSCHEIN, DR ;
MENG, YY ;
TORRBROWN, S ;
SOBEL, BE .
CIRCULATION, 1995, 92 (04) :944-949
[2]   AN ANTITISSUE FACTOR PATHWAY INHIBITOR (TFPI) MONOCLONAL-ANTIBODY RECOGNIZED THE 3RD KUNITZ DOMAIN (K3) OF FREE-FORM TFPI BUT NOT LIPOPROTEIN-ASSOCIATED FORMS IN PLASMA [J].
ABUMIYA, T ;
ENJYOJI, K ;
KOKAWA, T ;
KAMIKUBO, Y ;
KATO, H .
JOURNAL OF BIOCHEMISTRY, 1995, 118 (01) :178-182
[3]   DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES [J].
ANNEX, BH ;
DENNING, SM ;
CHANNON, KM ;
SKETCH, MH ;
STACK, RS ;
MORRISSEY, JH ;
PETERS, KG .
CIRCULATION, 1995, 91 (03) :619-622
[4]   CULTURED NORMAL HUMAN HEPATOCYTES DO NOT SYNTHESIZE LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR - EVIDENCE THAT ENDOTHELIUM IS THE PRINCIPAL SITE OF ITS SYNTHESIS [J].
BAJAJ, MS ;
KUPPUSWAMY, MN ;
SAITO, H ;
SPITZER, SG ;
BAJAJ, SP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8869-8873
[5]  
BAUER KA, 1987, BLOOD, V70, P343
[6]  
BROZE GJ, 1988, BLOOD, V71, P335
[7]   THE ROLE OF TISSUE FACTOR IN THE PRODUCTION OF THROMBIN [J].
CARSON, SD ;
BROZNA, JP .
BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (02) :281-292
[8]  
EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67
[9]   CDNA CLONING AND EXPRESSION OF RAT-TISSUE FACTOR PATHWAY INHIBITOR (TFPI) [J].
ENJYOJI, K ;
EMI, M ;
MUKAI, T ;
KATO, H .
JOURNAL OF BIOCHEMISTRY, 1992, 111 (05) :681-687
[10]   FUNCTIONAL-SIGNIFICANCE OF THE KUNITZ-TYPE INHIBITORY DOMAINS OF LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR [J].
GIRARD, TJ ;
WARREN, LA ;
NOVOTNY, WF ;
LIKERT, KM ;
BROWN, SG ;
MILETICH, JP ;
BROZE, GJ .
NATURE, 1989, 338 (6215) :518-520